HR Execs on the Move

Horizon Pharma

www.horizonpharma.com

 
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Emanuele Gueli
Sr. Director R&D Systems Profile
Irina Konstantinovsky
Executive Vice President and Chief Human Resources Officer Profile
Laura Lustig
Vice President - Human Resources Profile

Similar Companies

Cycle Pharmaceuticals

WHAT WE DO Cycle Pharmaceuticals is a global, privately-owned and patient-dedicated biotechnology company headquartered in Cambridge in the UK. Our mission is to utilise the latest pharmaceutical technologies to deliver superior drug treatments to b...

Alpharma, LLC

Alpharma, LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

BTL Industries

Founded in 1993, BTL has grown to become one of the world’s major manufacturers of medical equipment. BTLs major segments include physical therapy, cardiology and medical aesthetics.

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.